“透明是一种信心,更是一种责任。汤臣倍健希望打造料、全球品质眼见为实。”中国保健品的生命似乎总难长久,不少保健品的营销渠道也令人诟病,但有着“创业板保健品第一股”称号的汤臣倍健(300146)却与众不同。这家公司上市以来业绩表现一直不错,最近发布的中报显示,公司今年上半年实现营业收入7.52亿元,同比增长四成;净利润2.33亿元,同比增长近三成。与此同时,汤臣倍健股价也一路上扬,从年初的38元(复权后)翻至最高点66元。汤臣倍健的出色表现基于什么呢?或许,其备受关注 “Transparency is a kind of confidence, it is a kind of responsibility.” Tomson times health hope to create the material, the global quality of seeing is believing. “The life of Chinese health care products seems always difficult for a long time, many health products marketing channels are also criticized , But with ”GEM stocks the first unit," the title of Tomson times Kin (300,146) is different. The performance of the company since listing has been good, recently released mid-year report shows that the company achieved operating income of 752 million yuan in the first half of this year, an increase of 40%; net profit of 233 million yuan, an increase of nearly 30%. At the same time, Tomson times healthy stock prices have also been rising, from the beginning of 38 yuan (after the restoration) to the highest point of 66 yuan. Tomson times healthy performance based on what it is? Perhaps, its concern